If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
==== Non-competitive ==== A non-competitive inhibitor binds to a site other than where the substrate binds. The substrate still binds with its usual affinity and hence Km remains the same. However the inhibitor reduces the catalytic efficiency of the enzyme so that Vmax is reduced. In contrast to competitive inhibition, non-competitive inhibition cannot be overcome with high substrate concentration.
Temgicoluril is used in Latvia and Russia, as a pharmaceutical drug to treat anxiety and to prevent or reduce anxiety, unrest, fear, internal emotional tension and irritability, reduce neuroses and neurotic disorders, heartburns of non-coronary heart disease origin. These effects are not accompanied with relaxation of muscle tone and impaired coordination of movement, suppression of mental and physical activity, so the drug can be used without interruption of work or school. Temgicoluril does not have a direct effect on sleep, however, it enhances the effectiveness of sleep medicines and normalizes the course of disturbed sleep. Temgicoluril alleviates or eliminates the manifestations of nicotine dependence that occur after smoking cessation. Although temgicoluril does not cause mood swings or euphoria, habituation, nor addiction, withdrawal syndrome has been observed.
== Approval history == The US FDA New Drug Application (NDA) was granted approval in May 2012, for use in adults. The US FDA Supplemental New Drug Application (sNDA) for pediatric use was granted approved in August 2014. In Israel, the Israeli Ministry of Health granted approval in September 2012. In Brazil, the Brazilian Health Surveillance Agency (ANVISA) granted approval in March 2013. In Canada, Health Canada issued a Notice of Compliance in May 2014, for both adults and pediatric patients. Taliglucerase alfa is made by the Israeli biotherapeutics company Protalix and sold by the American pharmaceutical company Pfizer.
Former fighters have told the media that the pills helped them overcome their fear. Doctors report that the drug has dangerous side effects, including psychosis and brain damage. According to former fighters, hundreds became addicted to the pills they were given by brigade leaders without knowing what they were taking. Fenethylline use was associated with the rise of jihadist group ISIS. One 19-year-old fighter named Kareem, who said he fought alongside ISIS for more than a year, told CNN in 2014: "They gave us drugs, hallucinogenic pills that would make you go to battle not caring if you live or die." In February 2023, Israel's Ministry of Defense claimed to have thwarted an attempt to smuggle thousands of fenethylline tablets from the West Bank into the Gaza Strip. Hamas claimed it had seized 50,000 fenethylline pills on the border, and claimed Israel was attempting to dope Gaza. Israel has publicly stated that fenethylline was used during the October 7 attacks, but this has been doubted by Caroline Rose, director of New Lines Institute's Strategic Blind Spots Portfolio. Israeli forces said they had found fenethylline-containing tablets, powder, and liquid on the bodies of the attackers. Rose said that she had never seen fenethylline made in liquid form. While precursor chemicals for fenethylline tend to be in powdered form, she said, fenethylline itself is not commonly a powder.
Sources: en.wikipedia.org
=== Further reading === Ball, S. J. The Cold War: An International History, 1947–1991 (1998). British perspective Beschloss, Michael, and Strobe Talbott. At the Highest Levels:The Inside Story of the End of the Cold War (1993) Braithwaite, Rodric et al. "Could the Soviet Union Have Survived? We ask four historians whether the demise of one of the 20th century's superpowers was as inevitable as it now seems." History Today (Oct 2020) 70#10 pp 8–10 [online]. Brooks, Stephen G., and William C. Wohlforth. "Power, globalization, and the end of the Cold War: Reevaluating a landmark case for ideas." International Security 25.3 (2001): 5-53. [online] Engel, Jeffrey A. When the World Seemed New: George H. W. Bush and the End of the Cold War (2017) Gaddis, John Lewis. The United States and the End of the Cold War: Implications, Reconsiderations, Provocations (1992) online Garthoff, Raymond. The Great Transition: American-Soviet Relations and the End of the Cold War (1994) online Goertz, Gary and Jack S. Levy, eds. Causal explanations, necessary conditions, and case studies: World War I and the End of the Cold War (2005), 10 essays from political scientists; online Hogan, Michael, ed. The End of the Cold War. Its Meaning and Implications (1992) articles from Diplomatic History Kalinovsky, Artemy M. "New Histories of the End of the Cold War and the Late Twentieth Century." Contemporary European History 27.1 (2018): 149–161. online Kegley Jr, Charles W. "How did the Cold War die? Principles for an autopsy." Mershon International Studies Review 38.Supplement_1 (1994): 11–41.
states led by Democratic attorneys general filed a federal lawsuit against the Trump administration and its Department of Health and Human Services, challenging changes to the childhood vaccination schedule that reduced the number of routinely recommended immunisations and shifted some to "shared clinical decision-making". On August 10, 2026, Trump signed an executive order requiring the vaccine for measles, mumps, and rubella to be split into three separate shots, and recommending that "to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits".
When used as a seed treatment or seed coating on cotton, corn, seed potatoes, soybeans, sugar beets, tomatoes, wheat, and many other seeds, it elicits an innate immunity response in developing roots which destroys parasitic cyst nematodes without harming beneficial nematodes and organisms. Agricultural applications of chitosan can reduce environmental stress due to drought and soil deficiencies, strengthen seed vitality, improve stand quality, increase yields, and reduce fruit decay of vegetables, fruits and citrus crops . Horticultural application of chitosan increases blooms and extends the life of cut flowers and Christmas trees. The US Forest Service has conducted research on chitosan to control pathogens in pine trees and increase resin pitch outflow which resists pine beetle infestation. Chitosan has been studied for applications in agriculture and horticulture dating back to the 1980s. By 1989, chitosan salt solutions were applied to crops for improved freeze protection or to crop seed for seed priming. Shortly thereafter, chitosan salt received the first ever biopesticide label from the EPA, then followed by other intellectual property applications. Chitosan has been used to protect plants in space, as well, exemplified by NASA's experiment to protect adzuki beans grown aboard the space shuttle and Mir space station in 1997. NASA results revealed chitosan induces increased growth (biomass) and pathogen resistance due to elevated levels of β-(1→3)-glucanase enzymes within plant cells. NASA confirmed chitosan elicits the same effect in plants on earth.
Sources: en.wikipedia.org
== Myelin clearance == Myelin is a phospholipid membrane that wraps around axons to provide them with insulation. It is produced by Schwann cells in the PNS, and by oligodendrocytes in the CNS. Myelin clearance is the next step in Wallerian degeneration following axonal degeneration. The cleaning up of myelin debris is different for PNS and CNS. PNS is much faster and efficient at clearing myelin debris in comparison to CNS, and Schwann cells are the primary cause of this difference. Another key aspect is the change in permeability of the blood-tissue barrier in the two systems. In PNS, the permeability increases throughout the distal stump, but the barrier disruption in CNS is limited to just the site of injury.
=== Social ties === In the article "Finding Happiness after Harvard", George Vaillant concluded a study on what aspects of life are important for "successful living". In the 1940s, Arlie Bock, while in charge of the Harvard Health Services, started a study, selecting 268 Harvard students from graduating classes of 1942, '43, and '44. He sought to identify the aspects of life contributing to "successful living". In 1967, the psychiatrist George Vaillant continued the study, undertaking follow-up interviews to gauge the lives of many of the students. In 2000, Vaillant again interviewed these students as to their progress in life. Vaillant observed: health, close relationships, and how participants dealt with their troubles. Vaillant found a key aspect to successful living is healthy and strong relationships. A widely publicized study from 2008 in the British Medical Journal reported happiness in social networks may spread from person to person. Researchers followed nearly 5000 individuals for 20 years in the long-standing Framingham Heart Study and found clusters of happiness and unhappiness that spread up to 3 degrees of separation on average. Happiness tended to spread through close relationships like friends, siblings, spouses, and next-door neighbors; researchers reported happiness spread more consistently than unhappiness through the network. Moreover, the structure of the social network appeared to affect happiness, as people who were very central (with many friends, and friends of friends) were significantly happier than those on the network periphery.
The French are also known for their violet syrup, most commonly made from an extract of violets. In the United States, this French violet syrup is used to make violet scones and marshmallows. Viola essence flavours the liqueurs Creme Yvette, Creme de Violette, and Parfait d'Amour. It is also used in confectionery, such as Parma Violets and C. Howard's Violet candies.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.